



Supplementary Figure 1



Supplementary Figure 1 - Kaplan-Meier survival curve of *PTPN11* expression with overall survival using TCGA head and neck cancer patients cohort, plotted with default parameters using OShnscc (<http://bioinfo.henu.edu.cn/HNSC/HNSCList.jsp>).


OShnscc: Online consensus Survival tool for Head and Neck Squamous Cell Carcinoma; TCGA: The Cancer Genome Atlas; OS: overall survival; HR: hazard ratio; CI: confidence interval; mRNA: messenger RNA.

Supplementary Figure 2



Supplementary Figure 2 - Co-competition assays between non-transduced cells with either Non-targeting (NT) or *PTPN11* sgRNAs-transduced OSCC to validate dependency on *PTPN11*. The percentage of BFP-positive transduced cells obtained at different time points were normalized to the day 4 or 6 readings for respective sgRNAs. *PLK1* is a core essential gene included as a positive control. Negative controls include *CHAT* which is a non-essential gene across the panel of cell lines, and NT serves as a non-targeting control.

Supplementary Figure 3



Supplementary Figure 3 - Boxplot of CRISPR scores on *PTPN11* in *MTOR*-dependent OSCCs and *MTOR*-non-dependent OSCCs.

Supplementary Figure 4 – Uncropped western blot images

Fig. 1D




Fig. 3A Sensitive lines




Fig. 3A Resistant lines





Fig. 4D


Fig. 4D

Fig. 4D


PE/CA-PJ15

p-MEK (217/221)

1 6 24 (hrs)

TNO155 [1 μ M] - + - + - + - + - + - +

Everolimus [1nM] - - + + - - + + - - + +




PE/CA-PJ15

p-ERK (202/204)

1 6 24 (hrs)

TNO155 [1 μ M] - + - + - + - + - + - +

Everolimus [1nM] - - + + - - + + - - + +



PE/CA-PJ15

p-AKT (308)

1 6 24 (hrs)

TNO155 [1 μ M] - + - + - + - + - + - +

Everolimus [1nM] - - + + - - + + - - + +






Fig. 4D

TNO155 [1 μ M] - + - + - + - + - + - +


Everolimus [1nM] - - + + - - + + - - + +



1 6 24 (hrs)

TNO155 [1 μ M] - + - + - + - + - + - +

Everolimus [1nM] - - + + - - + + - - + +



1 6 24 (hrs)

TNO155 [1 μ M] - + - + - + - + - + - +

Everolimus [1nM] - - + + - - + + - - + +

